The growing role of genomics in cancer treatment was examined at the latest Weill Cornell Medicine-Qatar (WCM-Q) Grand Rounds.
Dr Susanna El Akiki, consultant clinical scientist in the diagnostic genomic division at Hamad Medical Corporation (HMC), gave a presentation which explained the difference between genetic and genomic analysis, described the technologies used to detect genomic changes, and discussed the impact of genomic reporting on therapeutic decision making. Dr El Akiki, who is an affiliate faculty member at WCM-Q, also explained how genomics has become central to precision cancer medicine.
What cancers all have in common is that they are due to changes in the genome, to mutations in the DNA, and it’s these mutations that disrupt the regulation of the cell cycle. My role as a diagnostic scientist is to use genetic technologies identify these mutations. We do this to confirm a diagnosis, to determine the prognosis of the patient, to risk stratify for treatment, to measure response to treatment, to monitor disease progression.’
Dr El Akiki explained that the new genetic sequencing technologies allow physicians to look at very large numbers of genes simultaneously, radically enhancing their ability to diagnose, monitor and target treatments at cancers. For example, targeted treatment of chronic myeloid leukemia (CML), a cancer of the white blood cells, with a therapy called tyrosine kinase inhibitors, had led to dramatic improvements in survival rates. Furthermore, by analysing the mutations in the patient’s genome, the physician can make an informed decision about which of the several tyrosine kinase inhibitors would be most effective.
If you look at the key milestones in the treatment of CML over the past 60 years, all of them were based on our improved understanding of the underlying genomics. Genomic medicine is really reshaping the delivery of pathology services as we go into this new era of cancer precision medicine, so it’s a very exciting time and a huge era of change.’
The lecture, titled ‘The Role of Genomics in Cancer Treatment’, was accredited by the Qatar Council for Healthcare Practitioners-Accreditation Department (QCHP-AD) and by the Accreditation Council for Continuing Medical Education (ACCME). For updates and more information about the WCM-Q Grand Rounds, visit qatar-weill.cornell.edu.
